国家: 加拿大
语言: 英文
来源: Health Canada
IPRATROPIUM BROMIDE (IPRATROPIUM BROMIDE MONOHYDRATE); SALBUTAMOL (SALBUTAMOL SULFATE)
BOEHRINGER INGELHEIM (CANADA) LTD LTEE
R03AL02
SALBUTAMOL AND IPRATROPIUM BROMIDE
20MCG; 100MCG
SOLUTION
IPRATROPIUM BROMIDE (IPRATROPIUM BROMIDE MONOHYDRATE) 20MCG; SALBUTAMOL (SALBUTAMOL SULFATE) 100MCG
INHALATION
4ML(120 PUFFS)
Prescription
ANTIMUSCARINICS ANTISPASMODICS
Active ingredient group (AIG) number: 0232902002; AHFS:
APPROVED
2014-01-10
_ _ _COMBIVENT RESPIMAT Product Monograph November 7, 2019 _ _Page 1 of 44 _ PRODUCT MONOGRAPH PR COMBIVENT ® RESPIMAT ® Ipratropium Bromide and Salbutamol Inhalation Solution (as Ipratropium Bromide Monohydrate and Salbutamol Sulfate) Each actuation delivers a dose of 20 mcg of ipratropium bromide and 100 mcg of salbutamol COMBIVENT ® RESPIMAT ® cartridge for use only with the COMBIVENT ® RESPIMAT ® Inhaler BRONCHODILATOR Boehringer Ingelheim (Canada) Ltd. 5180 South Service Road Burlington, Ontario L7L 5H4 Date of Revision: November 7, 2019 Submission Control No: 230157 Combivent ® Respimat ® is a registered trademark used under license by Boehringer Ingelheim (Canada) Ltd. CCDS 0204-07 _COMBIVENT RESPIMAT Product Monograph November 7, 2019 _ _Page 2 of 44 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ....................................................................................................8 DRUG INTERACTIONS ..................................................................................................12 DOSAGE AND ADMINISTRATION ..............................................................................13 OVERDOSAGE ................................................................................................................14 ACTION AND CLINICAL PHARMACOLOGY ............................................................14 STORAGE AND STABILITY ..........................................................................................20 SPECIAL HANDLING INSTRUCTIONS 阅读完整的文件